Kiniksa Pharmaceuticals Files 8-K

TL;DR

Kiniksa filed an 8-K on 6/5/25 for standard reporting - no major news.

AI Summary

Kiniksa Pharmaceuticals International, plc filed an 8-K on June 5, 2025, reporting information under Regulation FD and including financial statements and exhibits. The company, incorporated in England and Wales, has its principal executive offices in London. This filing does not appear to contain specific financial transaction details or material events beyond standard reporting requirements.

Why It Matters

This filing indicates standard corporate reporting activity for Kiniksa Pharmaceuticals, providing updates on financial statements and exhibits as required by the SEC.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any new risks or material events.

Key Players & Entities

• Kiniksa Pharmaceuticals International, plc (company) — Registrant
• June 5, 2025 (date) — Date of earliest event reported
• England and Wales (jurisdiction) — State or other jurisdiction of incorporation or organization
• London (location) — Address of principal executive offices

FAQ

From the Filing

0001104659-25-056665.txt : 20250605 0001104659-25-056665.hdr.sgml : 20250605 20250605071035 ACCESSION NUMBER: 0001104659-25-056665 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20250605 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250605 DATE AS OF CHANGE: 20250605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 251025017 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 8-K 1 tm2517185d1_8k.htm FORM 8-K false 0001730430 0001730430 2025-06-05 2025-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): June 5, 2025   Kiniksa Pharmaceuticals International, plc (Exact name of Registrant as Specified in Its Charter)   England and Wales   001-730430   98-1795578 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.)   23 Old Bond Street, Floor 3 London , W1S 4PZ England , United Kingdom (Address of principal executive offices, including zip code)   ( 781 ) 431-9100 (Registrant’s telephone number, including area code)   N/A (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Class A Ordinary Shares, $0.000273235 nominal value   KNSA   The Nasdaq Stock Market LLC         (Nasdaq Global Select Market)   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨           Item 7.01. Regulation FD Disclosure.   On June 5, 2025, Kiniksa Pharmaceuticals International, plc (the “Company”) issued a press release (the “Press Release”) announcing, among other things, (i) that its KPL-387 Phase 2/3 clinical trial in recurrent pericarditis was on track to initiate in mid-20